#ITI#A heterologous neuraminidase subtype strategy for the differentiation of infected and vaccinated animals (DIVA) for avian influenza virus using an alternative neuraminidase inhibition test#FTI#
#IRE#The option of vaccinating poultry against avian influenza (AI) as a control tool is gaining greater acceptance by governments and the poultry industry worldwide. One disadvantage about vaccination with killed whole-virus vaccines is the resulting inability to use common serologic diagnostic tests for surveillance to identify infected flocks. There has been considerable effort to develop a reliable test for the differentiation of infected from vaccinated animals (DIVA). The heterologous neuraminidase (NA) subtype DIVA approach has been used with some success in the field accompanied by an ad hoc serologic test. The traditional NA inhibition (NI) test can be used for all nine NA subtypes, but it is time consuming, and it is not designed to screen large numbers of samples. In this study, a quantitative NI test using MUN (2′-4-methylumbelliferyl-α-D-Nacetylneuraminic acid sodium salt hydrate) as an NA substrate was investigated as an alternative to the traditional fetuin-based NI test in a heterologous neuraminidase DIVA strategy. Serum NI activity was determined in chickens administered different vaccines containing different H5 and NA subtypes and challenged with a highly pathogenic avian influenza (HPAI) H5N2 virus. Prior to challenge, the NI DIVA test clearly discriminated between chickens receiving vaccines containing different antigens (e.g., N8 or N9) from control birds that had no NA antibody. Some birds began to seroconvert 1 wk postchallenge, and 100% of the vaccinated birds had significant levels of N2 NI activity. This activity did not interfere with the presence of vaccine-induced NI activity against N8 or N9 subtypes. The level of N2-specific NI activity continued to increase to the last sampling date, 4 wk postchallenge, indicating the potential use for the heterologous NA-based DIVA strategy in the field. © 2010 American Association of Avian Pathologists.#FRE#
#IPC#Chickens; Diagnostic; DIVA strategy; Influenza A virus; Neuraminidase inhibition test#FPC#
#IRF#Alexander D.J., Summary of avian influenza activity in Europe Asia Africa and Australasia 2002-2006, Avian Dis., 51, pp. 161-166, (2007); 
Avian influenza update: Recent outbreaks of H5N1 in poultry worldwide, Euro. Surveill., 12, (2007); 
Aymard-Henry M., Coleman M.T., Dowdle W.R., Laver W.G., Schild G.C., Webster R.G., Influenza virus neuraminidase and neuraminidase-inhibition test procedures, Bull. World Health Organ., 48, pp. 199-202, (1973); 
Beard C.W., To vaccinate or not to vaccinate, Second International Symposium on Avian Influenza, pp. 258-26, (1986); 
Bublot M., Pritchard N., Swayne D.E., Selleck P., Karaca K., Suarez D.L., Audonnet J.C., Mickle T.R., Development and use of fowlpox vectored vaccines for avian influenza, Ann. NY Acad. Sci., 1081, pp. 193-201, (2006); 
Capua I., Vaccination for notifiable avian influenza in poultry, Rev. Sci. Tech., 26, pp. 217-227, (2007); 
Capua I., Cattoli G., Marangon S., DIVA-a vaccination strategy enabling the detection of field exposure to avian influenza, Dev. Biol. (Basel), 119, pp. 229-233, (2004); 
Capua I., Marangon S., Vaccination policy applied for the control of avian influenza in Italy, Dev. Biol. (Basel), 114, pp. 213-219, (2003); 
Capua I., Marangon S., The challenge of controlling notifiable avian influenza by means of vaccination, Avian Dis., 51, pp. 317-322, (2007); 
Capua I., Terregino C., Cattoli G., Mutinelli F., Rodriguez J.F., Development of a DIVA (differentiating infected from vaccinated animals) strategy using a vaccine containing a heterologous neuraminidase for the control of avian influenza, Avian Pathol, 32, pp. 47-55, (2003); 
Cattoli G., Milani A., Bettini F., Serena Beato M., Mancin M., Terregino C., Capua I., Development and validation of an anti-N3 indirect immunofluorescent antibody test to be used as a companion diagnostic test in the framework of a "dIVA" vaccination strategy for avian influenza infections in poultry, Avian Pathol, 35, pp. 154-159, (2006); 
Garcia A., Johnson H., Srivastava D.K., Jayawardene D.A., Wehr D.R., Webster R.G., Efficacy of inactivated H5N2 influenza vaccines against lethal A/Chicken/Queretaro/19/95 infection, Avian Dis., 42, pp. 248-256, (1998); 
Halvorson D.A., The control of H5 or H7 mildly pathogenic avian influenza: A role for inactivated vaccine, Avian Pathol, 31, pp. 5-12, (2002); 
Ikonen N., Pyhala R., Toivonen M., Korpela H., Influenza A/ Fujian/411/02(H3N2)-lineage viruses in Finland: Genetic diversity, epidemic activity and vaccination-induced antibody response, Arch. Virol., 151, pp. 241-254, (2006); 
Lambrecht B., Steensels M., Van Borm S., Meulemans G., Berg Den T.Van, Development of an M2e-specific enzyme-linked immuno- sorbent assay for differentiating infected from vaccinated animals, Avian Dis., 51, pp. 221-226, (2007); 
Lee C.W., Senne D.A., Suarez D.L., Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (differentiating infected from vaccinated animals) strategy for the control of avian influenza, Vaccine, 22, pp. 3175-3181, (2004); 
Lee C.W., Suarez D.L., Avian influenza virus: Prospects for prevention and control by vaccination, Anim. Health Res. Rev., 6, pp. 1-15, (2005); 
Lee Y.J., Sung H.W., Choi J.G., Lee E.K., Jeong O.M., Kwon Y.K., Kwon J.H., Song C.S., Kim J.H., Effects of homologous and heterologous neuraminidase vaccines in chickens against H5N1 highly pathogenic avian influenza, Avian Dis., 51, pp. 476-478, (2007); 
Li D., Saito R., Le M.T., Nguyen H.L., Suzuki Y., Shobugawa Y., Dinh D.T., Hoang P.V., Tran H.T., Nghiem H.K., Hoang L.T., Huynh L.P., Nguyen H.T., Nishikawa M., Suzuki H., Genetic analysis of influenza A/H3N2 and A/H1N1 viruses circulating in Vietnam from 2001 to 2006, J. Clin. Microbiol., 46, pp. 399-405, (2008); 
Neumann G., Watanabe T., Ito H., Watanabe S., Goto H., Gao P., Hughes M., Perez D.R., Donis R., Hoffmann E., Hobom G., Kawaoka Y., Generation of influenza A viruses entirely from cloned cDNAs, Proc. Natl. Acad. Sci. U. S. A., 96, pp. 9345-9350, (1999); 
Powers D.C., Belshe R.B., Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: Effects of aging and "original antigenic sin, J. Infect. Dis., 169, pp. 1125-1129, (1994); 
Rameix-Welti M.A., Agou F., Buchy P., Mardy S., Aubin J.T., Veron M., Werf Der S.Van, Naffakh N., Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir, Antimicrob. Agents Chemother., 50, pp. 3809-3815, (2006); 
Reed L.J., Muench H., A simple method of estimating fifty percent endpoints, Am. J. Hyg., 27, pp. 493-497, (1938); 
Spackman E., Senne D.A., Myers T.J., Bulaga L.L., Garber L.P., Perdue M.L., Lohman K., Daum L.T., Suarez D.L., Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes, J. Clin. Microbiol., 40, pp. 3256-3260, (2002); 
Stone H.D., The preparation and efficacy of manually emulsified Newcastle disease oil-emulsion vaccines, Avian Dis., 35, pp. 8-16, (1991); 
Suarez D.L., Overview of avian influenza DIVA test strategies, Biologicals, 33, pp. 221-226, (2005); 
Suarez D.L., Lee C.W., Swayne D.E., Avian influenza vaccination in North America: Strategies and difficulties, Dev. Biol. (Basel), 124, pp. 117-124, (2006); 
Suarez D.L., Perdue M.L., Cox N., Rowe T., Bender C., Huang J., Swayne D.E., Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong, J. Virol., 72, pp. 6678-6688, (1998); 
Swayne D.E., Application of new vaccine technologies for the control of transboundary diseases, Dev. Biol. (Basel), 119, pp. 219-228, (2004); 
Swayne D.E., Principles for vaccine protection in chickens and domestic waterfowl against avian influenza: Emphasis on Asian H5N1 high pathogenicity avian influenza, Ann. NY Acad. Sci., 1081, pp. 174-181, (2006); 
Swayne D.E., Beck J.R., Garcia M., Stone H.D., Influence of virus strain and antigen mass on efficacy of H5 avian influenza virus inactivated vaccines, Avian Pathol., 28, pp. 245-256, (1999); 
Swayne D.E., Beck J.R., Perdue M.L., Beard C.W., Efficacy of vaccines in chickens against highly pathogenic Hong Kong H5N1 avian influenza, Avian Dis., 45, pp. 355-365, (2001); 
Swayne D.E., Lee C.W., Spackman E., Inactivated North American and European H5N2 avian influenza virus vaccines protect chickens from Asian H5N1 high pathogenicity avian influenza virus, Avian Pathol., 35, pp. 141-146, (2006); 
Swayne D.E., Senne D.A., Suarez D.L., Avian influenza, A Laboratory Manual for the Isolation, Identification, and Characterization of Avian Pathogens, pp. 128-134, (2008); 
Sylte M.J., Hubby B., Suarez D.L., Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection, Vaccine, 25, pp. 3763-3772, (2007); 
Tumpey T.M., Alvarez R., Swayne D.E., Suarez D.L., Diagnostic approach for differentiating infected from vaccinated poultry on the basis of antibodies to NS1, the nonstructural protein of influenza A virus, J. Clin. Microbiol., 43, pp. 676-683, (2005); 
Webster R.G., Kasel J.A., Couch R.B., Laver W.G., Influenza virus subunit vaccines. II. Immunogenicity and original antigenic sin in humans, J. Infect. Dis., 134, pp. 48-58, (1976); 
Zhao S., Jin M., Li H., Tan Y., Wang G., Zhang R., Chen H., Detection of antibodies to the nonstructural protein (NS1) of avian influenza viruses allows distinction between vaccinated and infected chickens, Avian Dis., 49, pp. 488-493, (2005)#FRF#
